Reuters – FDA advisers back MannKind’s inhaled diabetes drug

Overall, it voted 13-1 to recommend approval for patients with type 1 diabetes and unanimously backed it for those with type 2, adding that longer-term studies would still be needed to monitor possible side effects such as lung cancer. Read more



from DiabetesNews http://ift.tt/1ifrnxc